(CercleFinance.com) – Pixium Vision soared by more than 60% this Tuesday on the Paris Stock Exchange following the presentation of the 48-month conclusions of its trial in age-related macular degeneration (AMD).
According to the specialist in bionic vision systems, this study confirmed the results at 36 months, namely ‘well tolerated’ use of his subretinal prosthesis, which did not lead to a reduction in natural peripheral vision. .
After four years, the average gain in treated patients was 32 letters, which should be considered ‘clinically meaningful’ for patients with geographic atrophy caused by AMD according to the company.
This first trial aimed to evaluate the effectiveness and safety of its Prima photovoltaic retinal stimulation microchip 48 months after implantation in patients with severe central visual field degradation due to age-related macular degeneration (AMD). ) dry.
Pixium now plans to fully publish the results of its pivotal European study ‘PRIMAvera’, having recruited 38 patients, at the start of the second quarter of 2024.
At 11:15 a.m., the stock was set to rise after posting gains of up to 63%, making it by far the strongest increase on the Paris market.
As a reminder, the company is currently undergoing receivership proceedings and is actively seeking buyers, with a deadline of November 20 for the submission of offers.
Copyright (c) 2023 CercleFinance.com. All rights reserved.